Insmed Incorporated

0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS

Case Summary
Company Name: Insmed Incorporated
Stock Symbol : NASDAQ: INSM
Class Period Start: 03/18/2013
Class Period End: 06/08/2016
Lead Plaintiff motion: 09/13/2016
Date Filed: 07/15/2016
Type of Case: Securities Class Action
Court: U.S. District Court for the District of New Jersey
Summary:

Thieler Law Corp advises investors with losses exceeding $100,000 of the September 13, 2016 lead plaintiff deadline in a class action lawsuit filed against Insmed Incorporated (NASDAQ: INSM) (“Insmed” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Insmed Incorporated securities between March 18, 2013 and June 8, 2016, have until September 13, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Insmed Incorporated securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the data on which Insmed’s European marketing authorization application for Arikayce relied was not likely to support approval by the European Medicines Agency (“EMA”) for the treatment of nontuberculous mycobacteria (“NTM”) lung disease;  Arikayce’s approval by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were thus less likely and/or imminent than Insmed had led investors to believe; and as a result, defendants’ statements about Insmed’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On June 8, 2016, Insmed disclosed that it had removed its European marketing application from the European Medicines Agency for its lung disease drug Arikayce. Insmed said its data from a mid-stage clinical study didn't support enough evidence for an approval from the EMA. The Company said it will resubmit the application when data is available from a later study.

Following this news, NASDAQ:INSM stock fell more than 18% in after-hours trading.

If you were negatively impacted by your investment in Insmed Incorporated securities between March 18, 2013 and June 8, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185

Transactions
Buy date (mm/dd/yyyy) Number of shares Price per share
Sell date (mm/dd/yyyy) Number of shares Price per share
Please wait...